News | November 01, 2021
GlaxoSmithKline posts Q2FY22 consolidated PAT at Rs. 204.24 Cr
GlaxoSmithKline Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
GlaxoSmithKline Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
Dr. Reddy's Laboratories has reported consolidated financial results for the period ended September 30, 2021
Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021
Zydus Wellness Limited has reported consolidated financial results for the period ended September 30, 2021
Cipla has reported consolidated financial results for the period ended September 30, 2021
Torrent Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
Subscribe To Our Newsletter & Stay Updated
